Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.
BACKGROUND
Prostate-specific antigen (PSA) bounce after brachytherapy has been well-documented. This phenomenon has also been identified in patients undergoing stereotactic body radiation therapy (SBRT). While the parameters that predict PSA bounce have been extensively studied in prostate brachytherapy patients, this study is the first to analyze the clinical and pathologic predictors of PSA bounce in prostate SBRT patients.


METHODS
Our institution has maintained a prospective database of patients undergoing SBRT for prostate cancer since 2006. Our study population includes patients between May 2006 and November 2011 who have at least 18 months of follow-up. All patients were treated using the CyberKnife treatment system. The prescription dose was 35-36.25 Gy in five fractions.


RESULTS
One hundred twenty patients were included in our study. Median PSA follow-up was 24 months (range 18-78 months). Thirty-four (28%) patients had a PSA bounce. The median time to PSA bounce was 9 months, and the median bounce size was 0.50 ng/mL. On univariate analysis, only younger age (p = 0.011) was shown to be associated with an increased incidence of PSA bounce. Other patient factors, including race, prostate size, prior treatment by hormones, and family history of prostate cancer, did not predict PSA bounces. None of the tumor characteristics studied, including Gleason score, pre-treatment PSA, T-stage, or risk classification by NCCN guidelines, were associated with increased incidence of PSA bounces. Younger age was the only statistically significant predictor of PSA bounce on multivariate analysis (OR = 0.937, p = 0.009).


CONCLUSIONS
PSA bounce, which has been reported after prostate brachytherapy, is also seen in a significant percentage of patients after CyberKnife SBRT. Close observation rather than biopsy can be considered for these patients. Younger age was the only factor that predicted PSA bounce.
Division of Radiation Oncology, Winthrop-University Hospital , New York, NY , USA ; Stony Brook School of Medicine , New York, NY , USA.
Charles C
CC
Vu
Division of Radiation Oncology, Winthrop-University Hospital , New York, NY , USA.
Jonathan A
JA
Haas
Department of Urology, Winthrop-University Hospital , New York, NY , USA.
Aaron E
AE
Katz
Division of Radiation Oncology, Winthrop-University Hospital , New York, NY , USA.
Matthew R
MR
Witten
CyberKnife; PSA; SAbR; SBRT; prostate cancer